{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T02:41:36Z","timestamp":1768963296838,"version":"3.49.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000272","name":"DH | National Institute for Health Research","doi-asserted-by":"publisher","award":["11\/25\/03"],"award-info":[{"award-number":["11\/25\/03"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"DH | National Institute for Health Research","doi-asserted-by":"publisher","award":["11\/25\/03"],"award-info":[{"award-number":["11\/25\/03"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"DH | National Institute for Health Research","doi-asserted-by":"publisher","award":["11\/25\/03"],"award-info":[{"award-number":["11\/25\/03"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"DH | National Institute for Health Research","doi-asserted-by":"publisher","award":["11\/25\/03"],"award-info":[{"award-number":["11\/25\/03"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"DH | National Institute for Health Research","doi-asserted-by":"publisher","award":["11\/25\/03"],"award-info":[{"award-number":["11\/25\/03"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"DH | National Institute for Health Research","doi-asserted-by":"publisher","award":["11\/25\/03"],"award-info":[{"award-number":["11\/25\/03"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"DH | National Institute for Health Research","doi-asserted-by":"publisher","award":["11\/25\/03"],"award-info":[{"award-number":["11\/25\/03"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"DH | National Institute for Health Research","doi-asserted-by":"publisher","award":["11\/25\/03"],"award-info":[{"award-number":["11\/25\/03"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"DH | National Institute for Health Research","doi-asserted-by":"publisher","award":["11\/25\/03"],"award-info":[{"award-number":["11\/25\/03"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,1,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There is limited evidence on the optimal frequency of mammogram surveillance. At 5-year follow-up, the Mammo-50 trial found that, in patients aged 50+ and 3 years post diagnosis, less frequent mammograms were non-inferior to annual mammograms for breast-cancer-specific-survival, recurrence-free interval and overall survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A within-trial cost-effectiveness analysis compared annual versus less frequent mammogram surveillance over 5 years from healthcare and societal perspectives. Hospital Episodes Statistics captured hospital-based resource use. Health-related quality of life and other cost data were obtained via questionnaires at surveillance mammograms. A budget impact analysis estimated NHS savings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Less frequent surveillance led to cost savings of \u2212\u00a3543.88 (\u2212\u00a31116; \u00a326) and a small reduction in quality-adjusted life years (QALYs) of \u22120.02 (\u22120.095; 0.06) per patient. The incremental net monetary benefit at a \u00a320,000\/QALY threshold was \u00a3187 (\u2212\u00a31574; \u00a32027). Including societal costs increased savings to \u00a31543 per person (\u2212\u00a32416; \u2212\u00a3669), and cost-effectiveness. Projected NHS savings were \u00a3185.87 million over 6 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Less frequent mammogram surveillance is cost-effective. Uncertainty remains due to variability in costs and quality of life estimates, and missing data in the less frequent arm due to study design. Given the trial\u2019s non-inferiority findings, this strategy is recommended from healthcare and societal perspectives.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41416-025-03248-2","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T16:36:05Z","timestamp":1762446965000},"page":"252-258","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Annual versus less frequent mammographic surveillance in people with breast cancer aged 50 years and older in the UK (Mammo-50): cost-effectiveness and budget impact analysis"],"prefix":"10.1038","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0652-6877","authenticated-orcid":false,"given":"Paola","family":"Cocco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Bojke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Hulme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6015-7841","authenticated-orcid":false,"given":"Peter S.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Hopkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet A.","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Meads","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bethany","family":"Shinkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"3248_CR1","unstructured":"National Institute for Health Care Excellence. Early and locally advanced breast cancer: diagnosis and management [NG101]. 2023. https:\/\/www.nice.org.uk\/guidance\/ng101\/resources\/early-and-locally-advanced-breast-cancer-diagnosis-and-management-pdf-66141532913605."},{"key":"3248_CR2","doi-asserted-by":"publisher","unstructured":"Robertson C, Arcot Ragupathy SK, Boachie C, Dixon JM, Fraser C, Hern\u00e1ndez R, et al. The clinical effectiveness and cost-effectiveness of different surveillance mammography regimens after the treatment for primary breast cancer: systematic reviews registry database analyses and economic evaluation. 2011. https:\/\/doi.org\/10.3310\/hta15340.","DOI":"10.3310\/hta15340"},{"key":"3248_CR3","doi-asserted-by":"publisher","unstructured":"Bouganim N, Tsvetkova E, Clemons M, Amir E. Evolution of sites of recurrence after early breast cancer over the last 20 years: implications for patient care and future research. Breast Cancer Res Treat. 2013. https:\/\/doi.org\/10.1007\/s10549-013-2561-7.","DOI":"10.1007\/s10549-013-2561-7"},{"key":"3248_CR4","doi-asserted-by":"publisher","unstructured":"Vrieling C, Collette L, Fourquet A, Hoogenraad WJ, Horiot JC, Jager JJ, et al. Can patient-, treatment- and pathology-related characteristics explain the high local recurrence rate following breast-conserving therapy in young patients? Eur J Cancer. 2003. https:\/\/doi.org\/10.1016\/S0959-8049(03)00123-0.","DOI":"10.1016\/S0959-8049(03)00123-0"},{"key":"3248_CR5","doi-asserted-by":"publisher","unstructured":"Dunn JA, Donnelly P, Elbeltagi N, Marshall A, Hopkins A, Thompson AM, et al. Annual versus less frequent mammographic surveillance in people with breast cancer aged 50 years and older in the UK (Mammo-50): a multicentre, randomised, phase 3, non-inferiority trial. Lancet. 2025. https:\/\/doi.org\/10.1016\/S0140-6736(24)02715-6.","DOI":"10.1016\/S0140-6736(24)02715-6"},{"key":"3248_CR6","unstructured":"NHS Digital. Hospital Episode Statistics (HES). https:\/\/digital.nhs.uk\/data-and-information\/data-tools-and-services\/data-services\/hospital-episode-statistics. Accessed 1 Oct 2024."},{"key":"3248_CR7","unstructured":"National Institute for Health Care Excellence. Position statement on use of the EQ-5D-5L value set for England (updated October 2019) _ [Technology appraisal guidance]. 2019. https:\/\/www.nice.org.uk\/about\/what-we-do\/our-programmes\/nice-guidance\/technology-appraisal-guidance\/eq-5d-5l#:~:text=We%20do%20not%20recommend%20using,set%20for%20reference%2Dcase%20analyses."},{"key":"3248_CR8","unstructured":"van Buuren S, Groothuis-Oudshoorn K, Vink G, Schouten [ctb] R, Robitzsch A, Rockenschaub P, et al. mice: multivariate imputation by chained equations. https:\/\/cran.r-project.org\/web\/packages\/mice\/index.html. Accessed 1 Aug 2024."},{"key":"3248_CR9","doi-asserted-by":"crossref","unstructured":"Alexander Robitzsch A, Grund S, Henke T. miceadds: some additional multiple imputation functions, especially for \u2018mice\u2019. 2014. https:\/\/cran.r-project.org\/web\/packages\/miceadds\/index.html. Accessed 1 Aug 2024.","DOI":"10.32614\/CRAN.package.miceadds"},{"key":"3248_CR10","doi-asserted-by":"publisher","unstructured":"Faria R, Gomes M, Epstein D, White IR A. Guide to handling missing data in cost-effectiveness analysis conducted within randomised controlled trials. PharmacoEconomics. 2014. https:\/\/doi.org\/10.1007\/s40273-014-0193-3.","DOI":"10.1007\/s40273-014-0193-3"},{"key":"3248_CR11","unstructured":"NHS England. National Cost Collection 2023\/24. https:\/\/www.england.nhs.uk\/costing-in-the-nhs\/national-cost-collection\/. Accessed 1 Oct 2024."},{"key":"3248_CR12","unstructured":"British National Formulary. BNF (British National Formulary). https:\/\/bnf.nice.org.uk\/. Accessed 1 Oct 2024."},{"key":"3248_CR13","unstructured":"Department of Health and Social Care. Drugs and pharmaceutical electronic market information tool (eMIT)\u20141 January 2023 to December 2023. 2023. Personal Social Services Research Unit (University of Kent) & Centre for Health Economics (University of York). Accessed 30 Sept 2024."},{"key":"3248_CR14","unstructured":"Jones KC, Weatherly H, Birch S, Castelli A, Chalkley M, Dargan A, et al. Unit costs of health and social care 2023 manual. 2024. https:\/\/kar.kent.ac.uk\/105685\/."},{"key":"3248_CR15","unstructured":"NHS England. Annex D: Prices and cost adjustments 2023\/25 NHS Payment Scheme. 2023. https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2023\/03\/23-25NHSPS_Annex-D-Prices-and-cost-adjustments.pdf. Accessed 1 Oct 2024."},{"key":"3248_CR16","unstructured":"NHS England. Annex D: prices and cost adjustments\u20142024\/24 2023\/25 NHS Payment Scheme (amended). 2024. https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2023\/03\/23-25NHSPS-amended_Annex-D-Prices-and-cost-adjustments_2024-25.pdf. Accessed 1 Oct 2024."},{"key":"3248_CR17","unstructured":"Office for National Statistics. Consumer price inflation time series (MM23). 2024. https:\/\/www.ons.gov.uk\/economy\/inflationandpriceindices\/timeseries\/d7bt\/mm23. Accessed 1 Oct 2024."},{"key":"3248_CR18","unstructured":"National Institute for Health Care Excellence. NICE health technology evaluations the manual guidance. https:\/\/www.nice.org.uk\/process\/pmg36\/chapter\/economic-evaluation-2. Accessed 30 Sept 2024."},{"key":"3248_CR19","unstructured":"Canty A, Ripley B boot: Bootstrap Functions (Originally by Angelo Canty for S). https:\/\/cran.r-project.org\/web\/packages\/boot\/index.html. Accessed 1 Oct 2024."},{"key":"3248_CR20","unstructured":"Henningsen A, Hamann JF. systemfit: estimating systems of simultaneous equations. https:\/\/cran.r-project.org\/web\/packages\/systemfit\/index.html. Accessed 1 Oct 2024."},{"key":"3248_CR21","doi-asserted-by":"publisher","unstructured":"Sullivan SD, Mauskopf JA, Augustovski F, Jaime Caro J, Lee KM, Minchin M, et al. Budget impact analysis\u2014principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health. 2014. https:\/\/doi.org\/10.1016\/j.jval.2013.08.2291.","DOI":"10.1016\/j.jval.2013.08.2291"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03248-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03248-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03248-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T13:54:21Z","timestamp":1768917261000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03248-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1,31]]}},"alternative-id":["3248"],"URL":"https:\/\/doi.org\/10.1038\/s41416-025-03248-2","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]},"assertion":[{"value":"1 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JAD received funding from the National Institute for Health Research (NIHR) Senior Investigator Award (NIHR200274) and the NIHR Health Technology Assessment (HTA) grant (project reference 11\/25\/03) through the University of Warwick, which funded JAD, AM, AH and BS at the University of Warwick; CH, BS, and PSH at the University of Leeds. PSH received funding from NIHR, Lilly, Eisai, Novartis, Merck, Gilead, Sanofi, Roche, AstraZeneca, Novartis, AbbVie and SeaGen. DM received consultancy fees from Otsuka and Egetis. All other authors declared no conflict of interest in relation to this publication.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The trial protocol and all amendments were approved by the UK Health Research Authority (West Midlands Research Ethics Committee 13\/WM\/0419). Potential participants were provided with a participant information sheet with details of the study and written informed consent (including consent for remote longer-term follow-up of deaths through NHS Digital) was obtained for the study before randomisation. An independent data monitoring board reviewed the accumulating data annually and reported recommendations to an independent steering committee, who provided oversight of the conduct of the trial. The protocol can be accessed online. The trial was registered with the ISRCTN registry, ISRCTN48534559. The study was performance in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors consented to submit this manuscript for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}